QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
QQQ   306.12 (-1.36%)
AAPL   157.83 (-0.91%)
MSFT   272.29 (-0.54%)
META   199.81 (-1.16%)
GOOGL   103.37 (-1.48%)
AMZN   98.70 (-1.90%)
TSLA   191.15 (-3.25%)
NVDA   264.68 (+1.03%)
NIO   9.09 (-1.94%)
BABA   83.65 (-0.06%)
AMD   97.58 (+1.72%)
T   18.39 (-0.81%)
F   11.48 (-2.05%)
MU   58.17 (-0.78%)
CGC   1.88 (-4.57%)
GE   89.59 (-2.81%)
DIS   94.90 (-1.70%)
AMC   4.34 (-1.59%)
PFE   40.01 (-1.60%)
PYPL   74.34 (-3.10%)
NFLX   293.90 (-3.89%)
NASDAQ:BLRX

BioLineRx - BLRX News Today

$0.76
+0.02 (+2.70%)
(As of 03/22/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.70
$0.80
50-Day Range
$0.56
$0.74
52-Week Range
$0.55
$1.98
Volume
864,376 shs
Average Volume
269,583 shs
Market Capitalization
$46.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.


BLRX Media Mentions By Week

BLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLRX
News Sentiment

0.12

0.34

Average
Medical
News Sentiment

BLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLRX Articles
This Week

3

1

BLRX Articles
Average Week

SourceHeadline
finance.yahoo.com logoBioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
finance.yahoo.com - March 22 at 10:00 AM
sg.finance.yahoo.com logoBioLineRx Ltd. (BLRX.TA)
sg.finance.yahoo.com - March 20 at 2:46 PM
MarketBeat logoStockNews.com Begins Coverage on BioLineRx (NASDAQ:BLRX)
americanbankingnews.com - March 20 at 6:28 AM
finance.yahoo.com logoBioLineRx to Report 2022 Annual Financial Results on March 22, 2023
finance.yahoo.com - March 15 at 8:50 AM
finance.yahoo.com logoBioLineRx Ltd. (BLRX) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - March 12 at 7:05 AM
finance.yahoo.com logoBioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
finance.yahoo.com - March 6 at 10:04 AM
businesswire.com logoBIOLINERX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioLineRx Ltd. and Encourages Investors to Contact the Firm
businesswire.com - March 3 at 9:40 PM
businesswire.com logoThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioLineRx Ltd. (BLRX)
businesswire.com - March 3 at 2:35 PM
benzinga.com logoBioLineRx Ltd. (BLRX) Class Action Alert: Robbins LLP Urges Shareholders with Significant Losses in BioLineRx Ltd. to Contact the Firm
benzinga.com - January 27 at 8:43 AM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioLineRx Ltd. - BLRX
benzinga.com - January 23 at 10:04 AM
benzinga.com logoBronstein, Gewirtz & Grossman, LLC Notifies BioLineRx Ltd. (BLRX) Investors of Class Action and to Actively Participate
benzinga.com - January 17 at 12:12 AM
finance.yahoo.com logoBioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
finance.yahoo.com - January 4 at 10:36 AM
finance.yahoo.com logoBioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate
finance.yahoo.com - December 28 at 10:23 AM
finance.yahoo.com logoBioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
finance.yahoo.com - December 20 at 7:49 AM
finance.yahoo.com logoBLRX: Self-Commercialization in the US
finance.yahoo.com - December 5 at 2:56 PM
finance.yahoo.com logoBioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
finance.yahoo.com - November 15 at 11:13 AM
finance.yahoo.com logoBioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
finance.yahoo.com - November 10 at 8:14 PM
finance.yahoo.com logoBioLineRx to Report Third Quarter 2022 Results on November 15, 2022
finance.yahoo.com - November 10 at 8:14 PM
finance.yahoo.com logoBioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
finance.yahoo.com - November 4 at 5:45 PM
finance.yahoo.com logoBioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 3 at 11:02 AM
finance.yahoo.com logoBLRX: Cast Off the Bowlines: Aphexda Commercialization
finance.yahoo.com - November 2 at 7:58 PM
finance.yahoo.com logoBioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Yahoo Finance
finance.yahoo.com - September 28 at 8:06 PM
finance.yahoo.com logoBioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
finance.yahoo.com - September 27 at 7:48 AM
streetinsider.com logoForm 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com
streetinsider.com - September 21 at 4:10 PM
businesswire.com logoINVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100000 to Contact the Firm - Business Wire
businesswire.com - September 20 at 7:45 PM
finance.yahoo.com logoBioLineRx Announces $15 Million Registered Direct Offering - Yahoo Finance
finance.yahoo.com - September 19 at 5:55 PM
businesswire.com logoEQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX - Business Wire
businesswire.com - September 19 at 5:55 PM
seekingalpha.com logoBioLineRx stock slips on $15M securities offering - Seeking Alpha
seekingalpha.com - September 19 at 12:54 PM
finance.yahoo.com logoBioLineRx Announces $15 Million Registered Direct Offering
finance.yahoo.com - September 19 at 12:53 PM
streetinsider.com logoBioLineRx (BLRX) Enters $40M Non-Dilutive Debt Financing Agreement with Kreos Capital - StreetInsider.com
streetinsider.com - September 15 at 8:51 PM
finance.yahoo.com logoBioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
finance.yahoo.com - September 15 at 3:50 PM
finance.yahoo.com logoBioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
finance.yahoo.com - September 15 at 10:49 AM
finance.yahoo.com logoNew Therapeutics Options in Pancreatic Ductal Adenocarcinoma Pipeline as 40+ Key Companies are Working on Drug Profiles | DelveInsight - Yahoo Finance
finance.yahoo.com - September 14 at 2:45 PM
finance.yahoo.com logoBioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Yahoo Finance
finance.yahoo.com - September 14 at 3:31 AM
benzinga.com logoBioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixa - Benzinga
benzinga.com - September 13 at 5:30 PM
benzinga.com logoBioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortid - Benzinga
benzinga.com - September 12 at 6:31 PM
nasdaq.com logoBioLineRx Announces Submission Of Its First NDA - Quick Facts
nasdaq.com - September 12 at 1:31 PM
finance.yahoo.com logoBioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
finance.yahoo.com - September 12 at 7:58 AM
finance.yahoo.com logoGlobal Actinic Keratosis Treatment Market to Reach $10.08 Billion by 2027 at a CAGR of 10.61% - Yahoo Finance
finance.yahoo.com - September 2 at 3:34 PM
benzinga.com logoBLRX: September NDA - Benzinga
benzinga.com - August 23 at 4:07 PM
finance.yahoo.com logoBLRX: September NDA
finance.yahoo.com - August 18 at 1:27 PM
seekingalpha.com logoBioLineRx falls 9% as costs increase in second quarter - Seeking Alpha
seekingalpha.com - August 17 at 5:25 PM
investing.com logoBioLineRx Tops Q2 EPS by 12c By Investing.com - Investing.com
investing.com - August 16 at 4:22 PM
uk.investing.com logoBioLineRx Tops Q2 EPS by 12c By Investing.com - Investing.com UK
uk.investing.com - August 16 at 11:21 AM
seekingalpha.com logobiolinerx GAAP EPS of -$0.01 beats by $0.08 (NASDAQ:BLRX) - Seeking Alpha
seekingalpha.com - August 16 at 11:21 AM
finance.yahoo.com logoBioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - August 16 at 11:21 AM
benzinga.com logoBioLineRx to Report Second Quarter 2022 Results on August 16, 2022 - Benzinga
benzinga.com - August 11 at 5:04 PM
finance.yahoo.com logoPositive Data from the Clinical Phase I MAD Study with AlzeCure's Alzheimer's Pproject NeuroRestore ACD856 - Yahoo Finance
finance.yahoo.com - June 30 at 8:40 PM
finance.yahoo.com logoEvofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO - Yahoo Finance
finance.yahoo.com - June 30 at 10:39 AM
morningstar.com logoADRs End Lower; BioLineRx, Can-Fite BioPharma Trade Actively - Morningstar
morningstar.com - June 29 at 11:45 PM
Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BLRX) was last updated on 3/22/2023 by MarketBeat.com Staff